Results 31 to 40 of about 3,811,568 (245)

20(S)-protopanaxadiol inhibition of progression and growth of castration-resistant prostate cancer. [PDF]

open access: yesPLoS ONE, 2014
Castration-resistant progression of prostate cancer after androgen deprivation therapies remains the most critical challenge in the clinical management of prostate cancer.
Bo Cao   +14 more
doaj   +1 more source

Efficacy of enzalutamide in patients with metastatic hormone-sensitive and castration-refractory prostate cancer: authors’ experience

open access: yesМедицинский совет, 2021
Prostate cancer is one of the most common neoplasms in men. It currently ranks second in Russian Federation amongst male population in overall number of cases after only lung cancer and third in cancer mortality.
T. V. Ustinova   +5 more
doaj   +1 more source

Knowledge mapping of immunotherapy in castration-resistant prostate cancer: a bibliometric and visualized study (2003–2022)

open access: yesFrontiers in Urology, 2023
ObjectiveTo utilize bibliometric analysis to examine the literature about immunotherapy for castration-resistant prostate cancer published within the past two decades.
Xianfu Cai   +5 more
doaj   +1 more source

Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen. [PDF]

open access: yesPLoS ONE, 2012
As prostate cancer progresses to castration-resistant disease, there is an increase in signal transduction activity. Most castration-resistant prostate tumors continue to express the androgen receptor (AR) as well as androgen-responsive genes, despite ...
Hilary Whitworth   +7 more
doaj   +1 more source

Autocrine activation of MAPK signaling mediates intrinsic tolerance to androgen deprivation in LY6D prostate cancer cells

open access: yesCell Reports, 2023
Summary: The emergence of castration-resistant prostate cancer remains an area of unmet clinical need. We recently identified a subpopulation of normal prostate progenitor cells, characterized by an intrinsic resistance to androgen deprivation and ...
Ivana Steiner   +16 more
doaj   +1 more source

Single-Cell Analysis Identifies LY6D as a Marker Linking Castration-Resistant Prostate Luminal Cells to Prostate Progenitors and Cancer

open access: yesCell Reports, 2018
Summary: The exact identity of castrate-resistant (CR) cells and their relation to CR prostate cancer (CRPC) is unresolved. We use single-cell gene profiling to analyze the molecular heterogeneity in basal and luminal compartments.
João D. Barros-Silva   +14 more
doaj   +1 more source

Lutetium-177 Prostate-Specific Membrane Antigen-617 Treatment in Metastatic Castration-Resistant Prostate Adenocarcinoma: Results of Single-Center Experience

open access: yes, 2023
Objective: Lutetium-177 prostate-specific membrane antigen-617 is a novel alternative therapeutic option in metastatic castration-resistant prostate cancer, especially useful for patients who do not respond to standard therapy methods.
Maman, Adem, Adem Maman
core   +1 more source

Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 [PDF]

open access: yes, 2023
Background: Innovations in imaging and molecular characterisation together with novel treatment options have improved outcomes in advanced prostate cancer. However, we still lack high-level evidence in many areas relevant to making management decisions
Yu, EY   +568 more
core   +2 more sources

Gene Expression Profiling Analysis Reveals Putative Phytochemotherapeutic Target for Castration-Resistant Prostate Cancer

open access: yesFrontiers in Oncology, 2019
Prostate cancer is the leading cause of cancer death among men globally, with castration development resistant contributing significantly to treatment failure and death.
Solomon Oladapo Rotimi   +5 more
doaj   +1 more source

Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer

open access: yesSAGE Open Medicine, 2023
Objectives: To identify useful biomarkers by reviewing laboratory data for a predictor of the clinical course following treatment with radium-223 dichloride (Ra-223) in patients with metastatic castration-resistant prostate cancer.
Gen Kawaguchi   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy